Active Filter(s):
Details:
The acquisition will strengthen company's OmniAb® technology platform. Potential for two approvals of OmniAb-derived antibodies in 2021 with expected new royalty streams to Ligand.
Lead Product(s): Mono- and Bispecific human antibodies
Therapeutic Area: Oncology Product Name: OmniAb
Highest Development Status: Discovery Platform Product Type: Large molecule
Partner/Sponsor/Collaborator: Ligand Pharmaceuticals
Deal Size: $7.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition September 10, 2020